BioCryst Pharmaceuticals explained

BioCryst Pharmaceuticals, Inc.
Type:Public
Traded As:NASDAQ:
Russell 2000 Component
Location:Durham, North Carolina, US
Key People:Jon P. Stonehouse (president and CEO)
Industry:Healthcare
Products:RABIVAP
Revenue: $49 million (2019)[1]
Num Employees:110
Homepage:www.biocryst.com

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

History

The company was founded in 1986 by Charles E. Bugg and John A. Montgomery.[2] In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.[3]

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.[4] In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania.[5] However, BioCryst shareholders voted down the merger in July.[6]

Pipeline

BioCryst’s core development programs include:

External links

  1. BioCryst

Notes and References

  1. Web site: BioCryst Pharmaceuticals Revenue 2006-2021 | BCRX.
  2. Web site: About us . July 17, 2023.
  3. Web site: BioCryst named 29th fastest growing tech firm . Birmingham Business Journal . November 26, 2008 .
  4. News: BioCryst moving HQ to Durham. Ranii. David. News & Observer. October 14, 2010. October 14, 2010. dead. https://web.archive.org/web/20101017043235/http://www.newsobserver.com/2010/10/14/739369/biocryst-moving-hq-to-durham.html. October 17, 2010. mdy-all.
  5. News: Patchen . Tyler. BioCryst Pharmaceuticals to merge with Pennsylvania pharmaceutical company . 7 April 2021 . The Business Journals . 23 January 2018.
  6. Web site: BioCryst stockholders call off merger with Idera Pharmaceuticals. Hale . Conor . 11 July 2018. Fierce Biotech . 9 April 2021.
  7. Web site: FDA Approves Berotralstat as First Oral Hereditary Angioedema Prophylaxis. 2021-01-09. HCPLive. December 4, 2020 .
  8. Web site: Orladeyo (berotralstat) FDA Approval History. 2021-01-09. Drugs.com. en.
  9. Web site: BioCryst Oral Drugs for Viruses Galidesivir. 2021-01-09. BioCryst Pharmaceuticals. en.
  10. Web site: 2014-03-03. Broad-Spectrum Antiviral Effective Against Ebola, MERS-CoV. 2021-01-09. Global Biodefense. en-US.
  11. Web site: HHS Contracts with BioCryst Pharmaceuticals to Develop New Ebola Drug. 2021-01-09. Infection Control Today. March 31, 2015 .
  12. Web site: BioCryst starts COVID-19 trial of broad-spectrum antiviral. 2021-01-09. FierceBiotech. April 10, 2020. en.
  13. Web site: A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 - Full Text View - ClinicalTrials.gov. 2021-01-09. clinicaltrials.gov. en.
  14. News: Halford . Bethany. To conquer COVID-19, create the perfect pill . 22 June 2021 . Chemical & Engineering News . 20 May 2021.